Recent weeks have seen noteworthy financial shifts and corporate restructuring across biotech and pharmaceutical sectors. Companies such as Minghui Pharmaceutical secured $131 million in pre-IPO funding aimed at advancing oncological antibody therapies, while AnaptysBio and Acadia Pharmaceuticals released second-quarter financial results reflecting growth and strategic business shifts. Leadership transitions include the appointment of new executives at Geron and various industry hires. Meanwhile, Bio-Techne announced the divestiture of its Exosome Diagnostics business to MDxHealth in a transformative deal, signaling dynamic portfolio management efforts in the life sciences landscape.